期刊文献+

醋酸乌利司他合成工艺优化

Optimization of The Synthesis Process of Ulipristal Acetate
在线阅读 下载PDF
导出
摘要 本文在醋酸乌利司他现有合成路线的基础上,选择以双缩酮(22)为起始物料,通过环氧化、格氏反应、水解和乙酰化反应合成醋酸乌利司他(1)。鉴于路线工艺控制相关文献报道较为有限,本研究通过精确控制反应温度提高环氧化选择性,优化格氏反应温度和确定磷酸氢二钾为最佳水解反应试剂,从而有效提高产品纯度。最终建立了有效质量控制策略,成品液相单杂纯度小于0.10%,液相纯度达到99%以上,符合原料药质量标准。该工艺操作简单、稳定性高,已完成中试生产,为工业化应用提供技术支持。 This article systematically reviews the existing synthetic routes of ulipristal acetate and selects diketone as the starting material to prepare ulipristal acetate through epoxidation,Grignard reaction,hydrolysis,and acetylation.Given the limited literature reports on process control related to this route,this study significantly improved product quality by optimizing reaction conditions.Specifically,the selectivity of epoxidation was enhanced by precisely controlling the reaction temperature,and the purity of the product was effectively increased by optimizing the temperature of the Grignard reaction and identifying potassium hydrogen phosphate as the optimal hydrolysis conditions.A comprehensive quality control strategy was ultimately established,with the final product exhibiting a single impurity of less than 0.10%in liquid chromatography and a purity of over 99%,fully meeting the quality standards for active pharmaceutical ingredients.The optimized process is simple to operate,highly stable,and has been successfully scaled up to pilot production,providing reliable technical support for industrial applications.
作者 夏志强 汪玉琳 李岩 罗剑 姚倩 邹辉 杜乐 XIA Zhiqiang;WANG Yulin;LI Yan;LUO Jian;YAO Qian;ZOU Hui;DU Le(College of Pharmacy,Hunan Normal University,Changsha 410000,China;Changsha Jingyi Medical Technology Co.,Ltd.,Changsha 410000,China;School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Benxi 117004,China;Ordos Central Hospital,Ordos 017000,China)
出处 《合成化学》 2026年第2期121-130,共10页 Chinese Journal of Synthetic Chemistry
关键词 醋酸乌利司他 紧急避孕药 环氧化反应 格氏反应 杂质研究 ulipristal acetate emergency contraceptive pill epoxidation reaction grignard reaction impurity research
  • 相关文献

参考文献3

二级参考文献8

  • 1马培奇.2009年上半年全球首次批准新药[J].上海食品药品监管情报研究,2009(5):27-33. 被引量:1
  • 2Cook CE, Wani MC, Lee YW, et al. 11 β-Substituted proge- sterone analogs: WO, 8912448[P]. 1989-12-28. (CA 1990, 112: 198892).
  • 3Kim HK, Rao PN, Burdett JE Jr, et al. Method for preparing 17α-acetoxy- 11β- (4-N,N-dimethylaminophenyl) - 19- norpregna-4,9-diene-3,20-dione, intermediates useful in the method, and methods for the preparation of such intermediates: WO, 9630390 [P]. 1996-10-03. (CA 1996, 125: 329114).
  • 4Rao PN, Acosta CK, Bahr ML, et al. A practical large-scale synthesis of 17α-acetoxy-11β- (4-N,N- dimethylaminophenyl) - 19-norpregna-4,9-diene-3,20-dione (CDB-2914) [J]. Steroids, 2000, 65 (7) : 395-400.
  • 5Maryanoff BE, Maryanoff CA. Advances in Medicinal Chemistry [M]. Vol 1, Greenwich: JAI Press Inc., 1992: 137-174.
  • 6Kim HK, Rao PN, Simmons AM. Method for preparing 17α-ac etoxy- 11β- (4-N,N-dimethylaminophenyl) - 19- norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates: WO, 2004078709 [P]. 2004-09-16. (CA 2004, 141: 260932).
  • 7Dancsi L, Visky G, Tuba Z, et al. Industrial process for the synthesis of 17α-acetoxy- 11 β- E4- (N,N-dimethylamino) phenyl] - 19-norpregna-4,9-diene-3,20-dione and new intermediates of the process: WO, 2007144674 [P]. 2007-12-21. (CA2007, 148: 55255).
  • 8刘宏斌,高建永,韩广甸.醋酸乌利司他合成路线图解[J].中国医药工业杂志,2011,42(1):73-75. 被引量:8

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部